Lupin, Yabao Pharma collaborate to meet growing demand for pediatric formulations in China
Mumbai: Global pharma major Lupin Limited has announced that the company has entered into a strategic partnership with Yabao Pharmaceutical Co. Inc., to meet the growing demand for quality drugs with pediatric formulations in the Chinese markets. The demand for high quality pediatric medicines has been growing rapidly in China as a result of the government's support and policy measures.
The latest Chinese pediatric pharmaceutical market report indicates that the market for pediatric drugs in China is expected to reach 210 billion CNY (33 billion USD) in 2021, growing at a rate of 9.23%.
Dr. Fabrice Egros, President - Corporate Development and Growth Markets, Lupin said, "We are excited about this partnership as it paves the way for us to bring quality pediatric formulations to the growing needs of patients in China. In addition to marketing our pediatric products in the Chinese market, we intend to expand our collaboration in other strategic therapeutics areas such as cardiometabolic, central nervous system and gastro-enterology."
Mr. Wei Ren, President of Yabao said, "We are very pleased to be partnering with Lupin to further strengthen Yabao's leadership position in the pediatric market. Yabao strives to develop its pediatric pipeline to address the urgent unmet needs in the market and to serve the pediatric patients. Moreover, Yabao also looks forward to expanding the collaboration with Lupin in other areas."
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas.
Read also: Lupin ropes in Diana Amador-Toro as Senior Vice President, Global Compliance
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.